Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The GluN1 subunit N-terminal domain (NTD) is a distinct structural region of the obligatory GluN1 subunit within the N-methyl-D-aspartate (NMDA) receptor complex. As a member of the ionotropic glutamate receptor family, the NMDA receptor plays a fundamental role in excitatory synaptic transmission, neurodevelopment, and synaptic plasticity mechanisms like long-term potentiation (LTP) [PubMed: 24560577]. The GluN1 NTD functions as a sophisticated allosteric signaling hub, where the binding of various modulators—including polyamines, protons, and certain ions—regulates the receptor's gating kinetics and ion channel open probability [PubMed: 21460830]. Clinically, this domain is of paramount importance as the primary epitope for pathogenic autoantibodies in anti-NMDA receptor encephalitis, a condition characterized by the depletion of surface receptors and subsequent neuropsychiatric dysfunction [PubMed: 20871601]. Furthermore, the GluN1 NTD is a target for pharmacological intervention, as small molecules and antibodies modulating this domain are being explored for treating conditions ranging from schizophrenia to neurodegenerative disorders [PubMed: 28973445]. By serving as a site for subunit-specific allosteric control, the GluN1 NTD offers a unique pathway for fine-tuning NMDA receptor activity without the global blockade associated with pore-binding antagonists.
Allosteric modulation of the NMDA receptor; the NTD acts as a regulatory domain that, upon ligand binding, influences the opening frequency and duration of the ion channel pore [PubMed: 24560577].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor ionotropic, NMDA 1 (GluN1) subunit N-terminal domain (GluN1 NTD).